Verrica Pharmaceuticals Q4 EPS $(0.53), Inline, Sales $1.99M Beat $910.00K Estimate
Author: Benzinga Newsdesk | February 29, 2024 08:34am
Verrica Pharmaceuticals (NASDAQ:
VRCA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate. This is a 278.57 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.99 million which beat the analyst consensus estimate of $910.00 thousand by 118.46 percent. This is a 2.82K percent increase over sales of $68.00 thousand the same period last year.
Posted In: VRCA